Young Caitlin, Phillips Rhiannon, Ebenezer Louise, Zutt Rodi, Peall Kathryn J
Cardiff University School of Medicine, Cardiff University Cardiff United Kingdom.
Division of Population Medicine, School of Medicine Cardiff University Cardiff United Kingdom.
Mov Disord Clin Pract. 2020 Apr 9;7(4):419-430. doi: 10.1002/mdc3.12925. eCollection 2020 May.
There are no standardized clinical guidelines for the management of Parkinson's disease (PD) during pregnancy. Increasing maternal age would suggest that the incidence of pregnancy in women diagnosed with PD is likely to increase.
To evaluate the evidence for the treatment of PD during pregnancy and to canvass opinion from patients and clinical teams as to the optimum clinical management in this setting.
This involved (1) a literature review of available evidence for the use of oral medical therapy for the management of PD during pregnancy and (2) an anonymized survey of patients and clinical teams relating to previous clinical experiences.
A literature review identified 31 publications (148 pregnancies, 49 PD, 2 parkinsonism, 21 dopa-responsive dystonia, 32 restless leg syndrome, 1 schizophrenia, and 43 unknown indication) detailing treatment with levodopa, and 12 publications with dopamine agonists. Adverse outcomes included seizures and congenital malformations. Survey participation included patients (n = 7), neurologists (n = 35), PD nurse specialists (n = 50), obstetricians (n = 15), and midwives (n = 20) and identified a further 34 cases of pregnancy in women with PD. Common themes for suggested management included optimization of motor symptoms, preference for levodopa monotherapy, and normal delivery unless indicated by obstetric causes.
This study demonstrates the paucity of evidence for decision-making in the medical management of PD during pregnancy. Collaboration is needed to develop a prospective registry, with longitudinal maternal and child health outcome measures to facilitate consensus management guidelines.
目前尚无针对妊娠期帕金森病(PD)管理的标准化临床指南。产妇年龄的增加表明,被诊断为PD的女性怀孕的发生率可能会上升。
评估妊娠期PD治疗的证据,并就这种情况下的最佳临床管理征求患者和临床团队的意见。
这包括(1)对妊娠期PD口服药物治疗现有证据的文献综述,以及(2)对患者和临床团队关于既往临床经验的匿名调查。
文献综述确定了31篇出版物(148例妊娠,49例PD,2例帕金森综合征,21例多巴反应性肌张力障碍,32例不宁腿综合征,1例精神分裂症,43例适应证不明)详细描述了左旋多巴治疗情况,以及12篇关于多巴胺激动剂的出版物。不良结局包括癫痫发作和先天性畸形。参与调查的包括患者(n = 7)、神经科医生(n = 35)、PD护士专家(n = 50)、产科医生(n = 15)和助产士(n = 20),并确定了另外34例PD女性妊娠病例。建议管理的共同主题包括优化运动症状、倾向于左旋多巴单药治疗以及除非有产科原因否则选择正常分娩。
本研究表明,妊娠期PD药物管理决策的证据不足。需要开展合作以建立一个前瞻性登记处,并采用纵向母婴健康结局指标,以促进达成共识管理指南。